VivoSim Labs Inc. Appoints Tony Lialin as Chief Commercial Officer to Lead AI-Enabled Toxicology Services Expansion

Reuters
Aug 14
VivoSim Labs Inc. Appoints Tony Lialin as Chief Commercial Officer to Lead AI-Enabled Toxicology Services Expansion

VivoSim Labs Inc. has announced the appointment of Tony Lialin as Chief Commercial Officer. With over two decades of experience, Lialin will lead the go-to-market strategy, partnerships, and expansion of the company's AI-enabled toxicology services using 3D human tissue models. The appointment aims to enhance the company's San Diego-based services, delivering early-stage decision-ready insights for drug development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VivoSim Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9512301-en) on August 14, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10